Nutraceuticals alone or with ezetimibe aid in dyslipidemia

December 10, 2015
Nutraceuticals alone or with ezetimibe aid in dyslipidemia

(HealthDay)—For statin-intolerant patients with dyslipidemia with ischemic heart disease treated with percutaneous coronary intervention, nutraceuticals alone or in combination with ezetimibe improve the lipid profile, according to a study published in the Dec. 15 issue of The American Journal of Cardiology.

Giuseppe Marazzi, M.D., Ph.D., from the Istituto di Ricerca a Carattere Scientifico San Raffaele Pisana in Rome, and colleagues conducted a randomized, prospective study comparing the safety and efficacy of a combination of nutraceuticals (red yeast rice, policosanol, berberine, folic acid, coenzyme Q10, and astaxanthin) and ezetimibe for three months. Patients who did not achieve their could add the alternative treatment for an additional 12 months. The authors enrolled 100 patients who were dyslipidemic with treated with (50 to nutraceuticals and 50 to ezetimibe).

The researchers found that 14 patients in the nutraceutical group and none in the ezetimibe group achieved their therapeutic target ( <100 mg/dL) after three months. The therapeutic goal was reached by 72.8 percent of the combined therapy group and by 100 percent of the nutraceutical group at one-year follow-up. There were no reports of important undesirable effects.

"Nutraceuticals alone or in combination with ezetimibe are well tolerated and improve the lipid profile in statin-intolerant patients with coronary heart disease," the authors write. "Further studies are needed to assess long-term effects of nutraceuticals on mortality."

Explore further: Statin treatment linked to reduced risk of cataracts

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Statin treatment linked to reduced risk of cataracts

December 7, 2015
(HealthDay)—Statin treatment is associated with reduced risk of incident cataract development, according to a study published in the Dec. 15 issue of The American Journal of Cardiology.

Atorvastatin/Ezetimibe beats atorvastatin after PCI

July 29, 2015
(HealthDay)—For Japanese patients who have undergone percutaneous coronary intervention (PCI), atorvastatin plus ezetimibe is associated with improved outcomes versus atorvastatin alone, according to a study published in ...

Preventable onset of myocardial infarction through coadministration of two drugs

July 30, 2015
Ischemic heart disease is the leading cause of death in the world and second in Japan behind cancer. It causes blood vessels to become clogged or narrowed through the buildup of cholesterol plaque along the inside of artery ...

Ezetimibe reduces cardiovascular events in diabetics with recent acute coronary syndrome

August 30, 2015
Ezetimibe reduces cardiovascular events in patients with diabetes and a recent acute coronary syndrome, according to a subgroup analysis of the IMPROVE-IT trial presented at ESC Congress today by co-principal investigator ...

Ezetimibe not tied to higher cancer risk, mortality

November 12, 2014
(HealthDay)—Treatment with the lipid-lowering therapy ezetimibe/simvastatin is not associated with an increased risk of developing cancer or an increased risk of dying from cancer, according to research published in the ...

Significantly improved chance of heart attack survival with high-potency statin treatment

February 20, 2014
(Medical Xpress)—A study looking at the data of thousands of patients who suffered heart attacks has suggested treatment with high-potency statins offers a significantly improved chance of survival compared to those taking ...

Recommended for you

Innovative triple pill significantly lowers blood pressure, study finds

August 14, 2018
A new low dose three in one pill to treat hypertension could transform the way high blood pressure is treated around the world.

Drug repurposing study sheds light on heart disease risk

August 14, 2018
A team led by researchers at Brigham and Women's Hospital has developed a computational technique to reveal the unknown side effects—both good and bad—of hundreds of drugs. That knowledge could help pharmacologists discover ...

Rethinking the stroke rule 'time is brain'

August 13, 2018
In 1993, neurologist Camilo R. Gomez, MD, coined a phrase that for a quarter century has been a fundamental rule of stroke care: "Time is brain!"

High oxidative stress hampers males' production of powerful blood vessel dilator

August 13, 2018
Higher levels of oxidative stress in males results in lower levels of a cofactor needed to make the powerful blood vessel dilator nitric oxide, researchers report.

Epigenetic reprogramming of human hearts found in congestive heart failure

August 9, 2018
Congestive heart failure is a terminal disease that affects nearly 6 million Americans. Yet its management is limited to symptomatic treatments because the causal mechanisms of congestive heart failure—including its most ...

Older adults who get physical can lower their heart disease risk

August 8, 2018
Adults in their early 60s, who spend less time sitting and more time engaged in light to vigorous physical activity, benefit with healthier levels of heart and vessel disease markers, according to new research in Journal ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.